Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Wåhlander K[au]:

Search results

Items: 39

1.

Development of Human Target Validation Classification that Predicts Future Clinical Efficacy.

Karlsson C, Greasley PJ, Gustafsson D, Wåhlander K.

J Pharmacol Exp Ther. 2019 Feb;368(2):255-261. doi: 10.1124/jpet.118.250894. Epub 2018 Nov 27.

PMID:
30482795
2.

Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.

Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.

J Thromb Haemost. 2017 Apr;15(4):758-769. doi: 10.1111/jth.13641. Epub 2017 Feb 28.

PMID:
28135035
3.

Developing New Treatments for Heart Failure: Focus on the Heart.

Gheorghiade M, Larson CJ, Shah SJ, Greene SJ, Cleland JG, Colucci WS, Dunnmon P, Epstein SE, Kim RJ, Parsey RV, Stockbridge N, Carr J, Dinh W, Krahn T, Kramer F, Wahlander K, Deckelbaum LI, Crandall D, Okada S, Senni M, Sikora S, Sabbah HN, Butler J.

Circ Heart Fail. 2016 May;9(5). pii: e002727. doi: 10.1161/CIRCHEARTFAILURE.115.002727.

4.

Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects.

Westergren HU, Svedlund S, Momo RA, Blomster JI, Wåhlander K, Rehnström E, Greasley PJ, Fritsche-Danielson R, Oscarsson J, Gan LM.

Cardiovasc Diabetol. 2016 Feb 19;15:36. doi: 10.1186/s12933-016-0353-1.

5.

Supporting Active Patient and Health Care Collaboration: A Prototype for Future Health Care Information Systems.

Åhlfeldt RM, Persson A, Rexhepi H, Wåhlander K.

Health Informatics J. 2016 Dec;22(4):839-853. Epub 2015 Aug 10.

PMID:
26261220
6.

Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Lip GY, Rasmussen LH, Olsson SB, Jensen E, Hamrén B, Eriksson UG, Wåhlander K.

Br J Clin Pharmacol. 2015 Dec;80(6):1362-73. doi: 10.1111/bcp.12719. Epub 2015 Sep 22.

7.

Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells.

Larsson P, Bergh N, Lu E, Ulfhammer E, Magnusson M, Wåhlander K, Karlsson L, Jern S.

J Thromb Thrombolysis. 2013 Feb;35(2):185-92. doi: 10.1007/s11239-012-0831-6.

PMID:
23229086
8.

Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.

Wolzt M, Eriksson UG, Gouya G, Leuchten N, Kapiotis S, Elg M, Schützer KM, Zetterstrand S, Holmberg M, Wåhlander K.

Thromb Res. 2012 Apr;129(4):e83-91. doi: 10.1016/j.thromres.2011.08.018. Epub 2011 Sep 16.

PMID:
21925716
9.

Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Johansson S, Cullberg M, Eriksson UG, Elg M, Dunér K, Jensen E, Wollbratt M, Wåhlander K.

Int J Clin Pharmacol Ther. 2011 Apr;49(4):258-67. doi: 10.5414/CP201465.

PMID:
21429440
10.

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.

Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A, Aunes-Jansson M, Eriksson U, Wåhlander K; Steering Committee.

Thromb Res. 2011 Feb;127(2):91-9. doi: 10.1016/j.thromres.2010.11.012. Epub 2010 Dec 18.

PMID:
21172721
11.

Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.

Schützer KM, Svensson MK, Zetterstrand S, Eriksson UG, Wåhlander K.

Eur J Clin Pharmacol. 2010 Sep;66(9):903-10. doi: 10.1007/s00228-010-0849-7. Epub 2010 Jun 10.

PMID:
20535457
12.

Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study.

Walfridsson H, Johansson B, Englund A, Kennebäck G, Schwieler J, Kongstad O, Wåhlander K, Malm AR, Edvardsson N.

Clin Drug Investig. 2010;30(7):461-71. doi: 10.2165/11536300-000000000-00000.

PMID:
20528001
13.

Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, Wåhlander K.

Thromb Haemost. 2010 Mar;103(3):604-12. doi: 10.1160/TH09-07-0509. Epub 2010 Jan 13.

PMID:
20076850
14.

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.

Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF; Steering Committee.

Eur Heart J. 2009 Dec;30(23):2897-907. doi: 10.1093/eurheartj/ehp318. Epub 2009 Aug 18.

15.

Effects of IL-1beta and IL-6 on tissue-type plasminogen activator expression in vascular endothelial cells.

Larsson P, Ulfhammer E, Karlsson L, Bokarewa M, Wåhlander K, Jern S.

Thromb Res. 2008;123(2):342-51. doi: 10.1016/j.thromres.2008.03.013. Epub 2008 May 27.

PMID:
18502475
16.

Trousseau's syndrome - what is the evidence? A population-based autopsy study.

Ogren M, Bergqvist D, Wåhlander K, Eriksson H, Sternby NH.

Thromb Haemost. 2006 Mar;95(3):541-5.

PMID:
16525584
17.

Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.

Wåhlander K, Eriksson-Lepkowska M, Nyström P, Eriksson UG, Sarich TC, Badimon JJ, Kalies I, Elg M, Bylock A.

Thromb Haemost. 2006 Mar;95(3):447-53.

PMID:
16525572
18.

Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.

Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S; THRIVE III Investigators.

Br J Haematol. 2006 Apr;133(1):68-77.

PMID:
16512831
19.

Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.

Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S; THRIVE III Investigators.

Thromb Haemost. 2005 Sep;94(3):522-7.

PMID:
16268466
20.

Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Cullberg M, Eriksson UG, Wåhlander K, Eriksson H, Schulman S, Karlsson MO.

Clin Pharmacol Ther. 2005 Apr;77(4):279-90.

PMID:
15903126
21.
22.

No effect of encapsulation on the pharmacokinetics of warfarin.

Johansson S, Ohlsson L, Stenhoff H, Wåhlander K, Cullberg M.

Biopharm Drug Dispos. 2005 Apr;26(3):121-7.

PMID:
15751004
23.

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.

Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson A, Karlson BW, Sheth SB, Held P.

Thromb Res. 2005;115(1-2):9-18. Review. No abstract available.

PMID:
15567447
24.

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.

Wolzt M, Levi M, Sarich TC, Boström SL, Eriksson UG, Eriksson-Lepkowska M, Svensson M, Weitz JI, Elg M, Wåhlander K.

Thromb Haemost. 2004 Jun;91(6):1090-6.

PMID:
15175794
25.

Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.

Wolzt M, Boström SL, Svensson M, Wåhlander K, Grind M, Sarich TC.

Pathophysiol Haemost Thromb. 2003 Mar-Apr;33(2):68-74.

26.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators.

N Engl J Med. 2003 Oct 30;349(18):1713-21.

27.

Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.

Johansson S, Wåhlander K, Larson G, Ohlsson L, Larsson M, Eriksson UG.

Blood Coagul Fibrinolysis. 2003 Oct;14(7):677-84.

PMID:
14517494
28.

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.

Wolzt M, Wollbratt M, Svensson M, Wåhlander K, Grind M, Eriksson UG.

Eur J Clin Pharmacol. 2003 Oct;59(7):537-43. Epub 2003 Sep 4.

PMID:
12955372
29.

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S; Thrive Investigators.

J Thromb Haemost. 2003 Jan;1(1):41-7.

30.

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.

Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wåhlander K, Gustafsson D, Badimon JJ.

J Thromb Haemost. 2003 May;1(5):999-1004.

31.

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Wåhlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG.

Clin Pharmacokinet. 2003;42(8):755-64.

PMID:
12846596
32.

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.

Wåhlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H.

Thromb Res. 2002 Aug 15;107(3-4):93-9.

PMID:
12431473
33.

Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.

Wåhlander K, Larson G, Lindahl TL, Andersson C, Frison L, Gustafsson D, Bylock A, Eriksson BI.

Thromb Haemost. 2002 Apr;87(4):580-5.

PMID:
12008938
34.

Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.

Mattsson C, Menschiek-Lundin A, Wåhlander K, Lindahl TL.

Thromb Haemost. 2001 Aug;86(2):611-5.

PMID:
11522011
35.

Glucose-stimulated insulin biosynthesis depends on insulin-stimulated insulin gene transcription.

Leibiger B, Wahlander K, Berggren PO, Leibiger IB.

J Biol Chem. 2000 Sep 29;275(39):30153-6.

36.

Comparison of various D-dimer tests for the diagnosis of deep venous thrombosis.

Wåhlander K, Tengborn L, Hellström M, Olmarker AH, Peterson LE, Stigendal L, Larson G.

Blood Coagul Fibrinolysis. 1999 Apr;10(3):121-6.

PMID:
10357005
37.

Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes.

Juntti-Berggren L, Larsson O, Rorsman P, Ammälä C, Bokvist K, Wåhlander K, Nicotera P, Dypbukt J, Orrenius S, Hallberg A, et al.

Science. 1993 Jul 2;261(5117):86-90.

PMID:
7686306
38.

Alpha 2-adrenoreceptor stimulation does not inhibit L-type calcium channels in mouse pancreatic beta-cells.

Bokvist K, Ammälä C, Berggren PO, Rorsman P, Wåhlander K.

Biosci Rep. 1991 Jun;11(3):147-57.

PMID:
1659917
39.

Activation by adrenaline of a low-conductance G protein-dependent K+ channel in mouse pancreatic B cells.

Rorsman P, Bokvist K, Ammälä C, Arkhammar P, Berggren PO, Larsson O, Wåhlander K.

Nature. 1991 Jan 3;349(6304):77-9.

PMID:
1898674

Supplemental Content

Loading ...
Support Center